About Kritika Sarmah
Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist.
She earned her bachelor's degree in commerce and is currently pursuing the CFA program.
With her fundamental approach, she aims to help investors identify untapped investment opportunities.
Recent Articles By Kritika Sarmah
Should Investors Start Sinking Money into Netflix (NFLX) Before August Ends?
The streaming landscape is undergoing significant shifts with rising prices and a writers’ strike. While leading video streaming company Netflix (NFLX) added a whooping 5.90 million customers in the recent quarter, the stock is currently trading under its 50-day moving average. Hence, let us analyze if investors should buy NFLX shares now...
Clover Health Investments (CLOV) vs. Cigna (CI): Which Medical Stock is the Bigger Buy?
The ever-rising healthcare costs are boosting the insurance industry in the current economic landscape. While prominent industry players Clover Health (CLOV) and Cigna Group (CI) should benefit, let us analyze which is the bigger buy...
GameStop (GME) vs. ODP Corp. (ODP): Which is the Better Long-Term Buy?
The retail industry is poised for solid growth, thanks to the resilience of consumer spending. While leading retail stocks GameStop (GME) and ODP (ODP) stand to benefit, let us analyze which of the stocks is the better buy for the long term...
Is Vanguard FTSE Developed Markets ETF (VEA) a Solid Buy?
Amidst the volatility in the stock market, let us look at the prospects of prominent ETF Vanguard FTSE Developed Markets (VEA) and assess whether it represents a compelling investment opportunity. Keep reading...
3 Value Pharma Stocks to Keep Watching
The pharma industry’s ability to remain resilient in times of economic uncertainty offers an appealing investment opportunity. Hence, fundamentally sound pharma stocks Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), and Voyager Therapeutics (VYGR), which seem relatively undervalued to their peers, might be ideal additions to one’s watchlist. Read on...
Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?
The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value...
3 Large Cap ETFs Investors Are Watching Everyday
Amidst market turbulence, large-cap ETFs tend to deliver stability and reliable cash flows while demonstrating less volatility. Hence, fundamentally strong large-cap ETFs Vanguard Value (VTV), Vanguard High Dividend Yield (VYM) and iShares Russell 1000 Value (IWD) might be solid additions to one’s watchlist. Continue reading...
4 Education Stocks with a Strong Future
The widespread adoption of advanced technologies and the growing popularity of smart classrooms are boosting the education industry. Hence, fundamentally strong education stocks Pearson (PSO), Adtalem Global Education (ATGE), Perdoceo Education (PRDO), and Lincoln Educational Services (LINC), which are rated an A (Strong Buy) in our proprietary rating system, might be solid buys for steady returns. Read more...
Amazon.com (AMZN) vs. Meta Platforms (META): Which Stock Is Holding Strong in This Economy?
The internet industry has a promising future, driven by rising internet usage and changing consumer needs. While leading internet stocks Amazon.com (AMZN) and Meta Platforms (META) should benefit, let us analyze which stock exhibits strength in this economy...